Maree J. Webster

Maree J. Webster

Auto-generated profile, based on publicly available information

Maree J. Webster

Laboratory of Brain Research, Stanley Medical Research Institute, Rockville, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2002 in Molecular Psychiatry
Verified
Journal Article
Closed access
MWM J Webster
M J Webster
MKM B Knable
M B Knable
JOJ O'GRady
J O'GRady
JOJ Orthmann
J Orthmann
CWCynthia Shannon Weickert
Cynthia Shannon Weickert

1 October 2006 in Gene Expression Patterns
Verified
Journal Article
Closed access
MWM.J. Webster
M.J. Webster
MHM.M. Herman
M.M. Herman
JKJ.E. Kleinman
J.E. Kleinman
CWCynthia Shannon Weickert
Cynthia Shannon Weickert

1 December 2002 in Developmental Brain Research
Verified
Journal Article
Closed access
MWMaree J Webster
Maree J Webster
CWCynthia Shannon Weickert
Cynthia Shannon Weickert
MHMary M Herman
Mary M Herman
JKJoel E Kleinman
Joel E Kleinman

6 May 2014 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
MRM T Ray
M T Ray
CWCynthia Shannon Weickert
Cynthia Shannon Weickert
MWM J Webster
M J Webster
Abnormalities in brain-derived neurotrophic factor (BDNF)/trkB signaling have been implicated in the etiology of schizophrenia and mood disorders. Patients with schizophrenia, bipolar disorder (BPD) and major depression (MDD) have reduced levels of neurotrophins in their brains when compared with normal unaffected individuals; however, only a few brain areas have been examined to date. Owing to the broad range of symptoms manifested in these disorders, we hypothesized that multiple associative areas of the neocortex may be implicated and that the degree of change in BDNF and trkB−TK+ mRNA expression and the cortical region or layers involved may vary according to Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnosis. We compared BDNF and trkB−TK+ mRNA levels across all layers of the prefrontal cortex (dorsolateral prefrontal cortex, DLPFC), orbital frontal cortex (OFC), anterior cingulate cortex (ACC), inferior temporal gyrus (ITG) and superior temporal gyrus (STG) in four groups: schizophrenia, BPD, MDD and unaffected controls (n=60). BDNF mRNA levels were significantly decreased in layers IV and V of DLPFC in schizophrenia patients, in layer VI of ACC in schizophrenia and MDD and in layer VI of ITG in schizophrenia, BPD and MDD. BDNF mRNA levels were also significantly decreased in layer V and/or VI of STG in schizophrenia, BPD and MDD. TrkB−TK+ mRNA levels were only significantly decreased in the cortical layer VI of OFC in BPD. The shared and distinct patterns of neurotrophin transcript reductions, with some specific to each group, may compromise the function and plasticity of distinct cortical areas to various degrees in the different groups and contribute to the range and overlap of symptoms manifested across the diagnoses.

24 July 2012 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
LLLeonora E Long
Leonora E Long
JLJonna Lind
Jonna Lind
MWMaree Webster
Maree Webster
CWCynthia Shannon Weickert
Cynthia Shannon Weickert
Background: Endocannabinoids provide control over cortical neurotransmission. We investigated the developmental expression of key genes in the endocannabinoid system across human postnatal life and determined whether they correspond to the development of markers for inhibitory interneurons, which shape cortical development. We used microarray with qPCR validation and in situ hybridisation to quantify mRNA for the central endocannabinoid receptor CB1R, endocannabinoid synthetic enzymes (DAGLα for 2-arachidonylglycerol [2-AG] and NAPE-PLD for anandamide), and inactivating enzymes (MGL and ABHD6 for 2-AG and FAAH for anandamide) in human dorsolateral prefrontal cortex (39 days - 49 years). Results: CB1R mRNA decreases until adulthood, particularly in layer II, after peaking between neonates and toddlers. DAGLα mRNA expression is lowest in early life and adulthood, peaking between school age and young adulthood. MGL expression declines after peaking in infancy, while ABHD6 increases from neonatal age. NAPE-PLD and FAAH expression increase steadily after infancy, peaking in adulthood. Conclusions: Stronger endocannabinoid regulation of presynaptic neurotransmission in both supragranular and infragranular cortical layers as indexed through higher CB1R mRNA may occur within the first few years of human life. After adolescence, higher mRNA levels of the anandamide synthetic and inactivating enzymes NAPE-PLD and FAAH suggest that a late developmental switch may occur where anandamide is more strongly regulated after adolescence than earlier in life. Thus, expression of key genes in the endocannabinoid system changes with maturation of cortical function.